- Report
- August 2024
- 200 Pages
Global
From €3445EUR$3,869USD£2,958GBP
- Report
- June 2024
- 140 Pages
Africa, Middle East
From €3445EUR$3,869USD£2,958GBP
- Report
- June 2024
- 140 Pages
Asia Pacific
From €3445EUR$3,869USD£2,958GBP
- Report
- June 2024
- 140 Pages
Europe
From €3445EUR$3,869USD£2,958GBP
- Report
- June 2024
- 140 Pages
Latin America
From €3445EUR$3,869USD£2,958GBP
- Report
- April 2024
- 140 Pages
Global
From €4406EUR$4,949USD£3,784GBP
- Report
- March 2023
- 147 Pages
Global
From €4406EUR$4,949USD£3,784GBP
- Report
- July 2025
- 350 Pages
Global
From €4406EUR$4,949USD£3,784GBP
- Report
- July 2024
- 109 Pages
Global
From €4229EUR$4,750USD£3,632GBP
- Report
- May 2024
- 128 Pages
Global
From €3561EUR$4,000USD£3,058GBP
- Report
- July 2025
- 217 Pages
Global
From €4447EUR$4,995USD£3,819GBP
- Report
- August 2025
- 150 Pages
Global
From €2814EUR$3,160USD£2,416GBP
€3517EUR$3,950USD£3,020GBP
- Report
- May 2025
- 140 Pages
Global
From €3517EUR$3,950USD£3,020GBP
- Report
- May 2026
- 150 Pages
Japan
From €4318EUR$4,850USD£3,708GBP
- Report
- May 2026
- 150 Pages
Spain
From €4318EUR$4,850USD£3,708GBP
- Report
- May 2026
- 150 Pages
United Kingdom
From €4318EUR$4,850USD£3,708GBP
- Report
- May 2026
- 150 Pages
Canada
From €4318EUR$4,850USD£3,708GBP
- Report
- May 2026
- 150 Pages
Germany
From €4318EUR$4,850USD£3,708GBP
- Report
- March 2026
- 150 Pages
Germany
From €4318EUR$4,850USD£3,708GBP
- Report
- March 2026
- 381 Pages
China
From €4318EUR$4,850USD£3,708GBP

The Dry Powder Inhaler (DPI) market is a segment of the respiratory drugs market. It is a device used to deliver medication to the lungs in the form of a dry powder. It is a convenient and efficient way to deliver medication to the lungs, as it does not require the use of a propellant gas. DPIs are used to treat a variety of respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. They are also used to deliver vaccines and other medications.
DPIs are becoming increasingly popular due to their convenience and effectiveness. They are also cost-effective, as they require fewer components than other inhalers. Additionally, DPIs are easy to use and can be used by patients of all ages.
Several companies are involved in the DPI market, including GlaxoSmithKline, Boehringer Ingelheim, Novartis, Merck, and AstraZeneca. These companies are involved in the development, manufacture, and marketing of DPIs. Show Less Read more